A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity - PubMed

Review

A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity

Anna Astashkina et al. Pharmacol Ther. 2012 Apr.

Abstract

Drug candidate and toxicity screening processes currently rely on results from early-stage in vitro cell-based assays expected to faithfully represent essential aspects of in vivo pharmacology and toxicology. Several in vitro designs are optimized for high throughput to benefit screening efficiencies, allowing the entire libraries of potential pharmacologically relevant or possible toxin molecules to be screened for different types of cell signals relevant to tissue damage or to therapeutic goals. Creative approaches to multiplexed cell-based assay designs that select specific cell types, signaling pathways and reporters are routine. However, substantial percentages of new chemical and biological entities (NCEs/NBEs) that fail late-stage human drug testing, or receive regulatory "black box" warnings, or that are removed from the market for safety reasons after regulatory approvals all provide strong evidence that in vitro cell-based assays and subsequent preclinical in vivo studies do not yet provide sufficient pharmacological and toxicity data or reliable predictive capacity for understanding drug candidate performance in vivo. Without a reliable translational assay tool kit for pharmacology and toxicology, the drug development process is costly and inefficient in taking initial in vitro cell-based screens to in vivo testing and subsequent clinical approvals. Commonly employed methods of in vitro testing, including dissociated, organotypic, organ/explant, and 3-D cultures, are reviewed here with specific focus on retaining cell and molecular interactions and physiological parameters that determine cell phenotypes and their corresponding responses to bioactive agents. Distinct advantages and performance challenges for these models pertinent to cell-based assay and their predictive capabilities required for accurate correlations to in vivo mechanisms of drug toxicity are compared.

Similar articles

• Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery.

  Prestwich GD. Prestwich GD. Acc Chem Res. 2008 Jan;41(1):139-48. doi: 10.1021/ar7000827. Epub 2007 Jul 27. Acc Chem Res. 2008. PMID: 17655274 Review.

• Understanding mechanisms of toxicity: insights from drug discovery research.

  Houck KA, Kavlock RJ. Houck KA, et al. Toxicol Appl Pharmacol. 2008 Mar 1;227(2):163-78. doi: 10.1016/j.taap.2007.10.022. Epub 2007 Nov 4. Toxicol Appl Pharmacol. 2008. PMID: 18063003 Review.

• The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.

  Amacher DE. Amacher DE. Toxicol Appl Pharmacol. 2010 May 15;245(1):134-42. doi: 10.1016/j.taap.2010.02.011. Epub 2010 Feb 26. Toxicol Appl Pharmacol. 2010. PMID: 20219512 Review.

• High-throughput human metabolism and toxicity analysis.

  Lee MY, Dordick JS. Lee MY, et al. Curr Opin Biotechnol. 2006 Dec;17(6):619-27. doi: 10.1016/j.copbio.2006.09.003. Epub 2006 Oct 12. Curr Opin Biotechnol. 2006. PMID: 17046235 Review.

• The use of 3-D cultures for high-throughput screening: the multicellular spheroid model.

  Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. Kunz-Schughart LA, et al. J Biomol Screen. 2004 Jun;9(4):273-85. doi: 10.1177/1087057104265040. J Biomol Screen. 2004. PMID: 15191644 Review.

Cited by

• Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance.

  Lim J, Ching H, Yoon JK, Jeon NL, Kim Y. Lim J, et al. Nano Converg. 2021 Apr 13;8(1):12. doi: 10.1186/s40580-021-00261-y. Nano Converg. 2021. PMID: 33846849 Free PMC article. Review.

• Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors.

  Zuo Y, Li R, Zhang Y, Bao G, Le Y, Yan L. Zuo Y, et al. J Enzyme Inhib Med Chem. 2022 Dec;37(1):2742-2754. doi: 10.1080/14756366.2022.2128797. J Enzyme Inhib Med Chem. 2022. PMID: 36176072 Free PMC article.

• Tissue-Engineered Models of the Human Brain: State-of-the-Art Analysis and Challenges.

  Tarricone G, Carmagnola I, Chiono V. Tarricone G, et al. J Funct Biomater. 2022 Sep 9;13(3):146. doi: 10.3390/jfb13030146. J Funct Biomater. 2022. PMID: 36135581 Free PMC article. Review.

• Efficient Generation of Functional Hepatocytes from Human Induced Pluripotent Stem Cells for Disease Modeling and Disease Gene Discovery.

  Kumar S, Curran JE, Williams-Blangero S, Blangero J. Kumar S, et al. Methods Mol Biol. 2022;2549:85-101. doi: 10.1007/7651_2021_375. Methods Mol Biol. 2022. PMID: 33772461 Free PMC article.

• Tissue-Engineered 3D In Vitro Disease Models for High-Throughput Drug Screening.

  Huskin G, Chen J, Davis T, Jun HW. Huskin G, et al. Tissue Eng Regen Med. 2023 Jul;20(4):523-538. doi: 10.1007/s13770-023-00522-3. Epub 2023 Mar 9. Tissue Eng Regen Med. 2023. PMID: 36892736 Free PMC article. Review.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database